高通量测序在肝硬化患者腹水、血清及粪便微生物群检测中的应用

Advances in the clinical application of high-throughput sequencing in detecting microbiota in cirrhotic ascites,serum,and feces

肝硬化是慢性进展性肝病,且肝硬化患者极易发生感染,尤其腹水、血清、粪便的菌群变化与肝硬化的进展及并发症有关。但是,大多数患者因腹水、血液中的细菌丰度低无法进行有效的细菌培养,因此难以进行全面分析。二代测序技术的高通量和高速度优势可以用于病原体生物学及临床诊断,包括病原体检测和鉴定、菌株分型、微生物组学研究,从而帮助临床医师优化抗菌药物的使用。目前,二代测序技术不断成熟,临床上对微生物群的全基因组进行分析成为可能。

Liver cirrhosis is a chronic progressive liver disease,and patients with liver cirrhosis are highly susceptible to infection.The changes in microbiota in ascites,serum,and feces are associated with the progression and complications of liver cirrhosis.However,effective bacterial culture cannot be performed for most patients due to low bacterial abundance in ascites and blood,and thus it is difficult to conduct a comprehensive analysis.The high-throughput and high-speed advantages of next-generation sequencing technique can be used for pathogen biology and clinical diagnosis,including pathogen detection and identification,strain typing,and microbiome studies,to help clinicians optimize the application of antimicrobials.At present,the next-generation sequencing technique gradually becomes mature,making it possible to analyze the whole genome of microbiota.